Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H44N6O5 |
Molecular Weight | 604.7397 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C2=NC3=CC=CC=C3C=C2)C(=O)NC(C)(C)C
InChI
InChIKey=ZILOOGIOHVCEKS-HZFUHODCSA-N
InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1
Telinavir (previously known as SC-52151) was developed as an anti-HIV aspartyl protease inhibitor for the treatment of HIV Infections. Telinavir participated in Phase I/II clinical study. In spite of the drug was well tolerated no antiviral activity was produced and further development of the drug was discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9215651
Forty-nine patients received the elixir or self-emulsifying drug delivery system at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C97366
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
382974
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
100000082442
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
SUB10872MIG
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
DTXSID60931785
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
GG-69
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
670881
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
IZF55EH3CG
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
143224-34-4
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL322241
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
7372
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
C76911
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY | |||
|
DB12178
Created by
admin on Fri Dec 15 16:16:58 GMT 2023 , Edited by admin on Fri Dec 15 16:16:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY